Exelixis, Inc. EXEL today announced updated results from BRIM7,
an ongoing phase 1b clinical trial conducted by Roche and Genentech,
Exelixis' collaborator and a member of the Roche Group (SIX: RO, ROG;
OTC: RHHBY), of the BRAF inhibitor (BRAFi) vemurafenib in combination
with the MEK inhibitor cobimetinib (GDC-0973/XL518) in patients with
locally advanced/unresectable or metastatic melanoma carrying a BRAFV600
mutation. Grant McArthur, M.D., Head of the Medical Oncology Skin and
Melanoma Clinical Service at the Peter MacCallum Cancer Centre in
Australia, and an investigator on the trial, presented the data today at
the European Cancer Congress (ECC) 2013 (Abstract #3703) which is taking
place in Amsterdam, The Netherlands.
“The data presented today,
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in